Published by BioScientifica
Society for Endocrinology Annual Meeting 2005

Society for Endocrinology Annual Meeting 2005

London, UK
07 November 2005 - 09 November 2005
Society for Endocrinology

Endocrine Abstracts (2005) 10 DP6

Triple oral therapy in diabetes – a case

BD Zalin

Hemel Hempstead Hospital, Hemel Hempstead, HERTS, United Kingdom.

  1. 58 year old man – Mr CB

  2. Type 2 diabetes for 16 years

  3. Well controlled hypertension

  4. Microalbuminuria with ACR 19

  5. Persistent haematuria with stone disease

  6. No retinopathy or neuropathy

  7. No macrovascular disease

  8. Otherwise fit and well

  9. Obese with BMI 33, not responsive to dietary modification

  10. Dyslipidaemic with Cholesterol 6.4, Trigs 5.9

  11. On Metformin 1 g tds, Lisinopril 2.5 mg od, Bezafibrate MR 400 mg od, Aspirin 75 mg od

  12. Persistently high HbA1cs of around 10%

  13. Initiated on Rosiglitazone 4 mg od

  14. Weight unchanged

  15. Continued sub optimal control after 6 months but slight improvement in HbA1c to 9.3%

  16. Would you initiate insulin treatment at this stage; increase Rosiglitazone to 8 mg od or add a sulphonylurea?

  17. Trial of Gliclazide 80 mg od

  18. Also changed fibrate to Simvastatin 40 mg on

  19. HbA1c improved to 7.3%

  20. Persistently reasonable

  21. Last HbA1c 6.5%

  22. Cholesterol 4.2, HDL 0.9, Trigs 2.1

  23. A vindication for the unlicensed triple oral therapy approach?

Endocrine Abstracts (2005) 10 DP6